547
Views
10
CrossRef citations to date
0
Altmetric
Clinical Studies

Inflammation and Overweight in Peritoneal Dialysis: Is There an Association?

, , , , , , & show all
Pages 549-554 | Received 10 Mar 2009, Accepted 17 May 2009, Published online: 09 Sep 2009
 

Abstract

More than 30% of the patients on peritoneal dialysis show chronic systemic inflammatory activity with high levels of C-reactive protein. The purpose of this cross-sectional study was to investigate the influence of the inflammatory state on clinical and nutritional markers in patients on peritoneal dialysis. Twenty-seven patients were included: mean age was 57.6 ± 19 years, 48% were male, and median time on peritoneal dialysis was 16.0 (8.3; 35.8) months. Clinical, dialytic, laboratory, anthropometric and electric bioimpedance data were collected with the sample stratified for C-reactive protein. In patients, the levels of Interleukin-6 and tumor necrosis factor-α were higher, while adiponectin levels were lower than in healthy individuals (p ≤ 0.001), indicating the presence of inflammatory activity in the sample. When compared to patients with C-reactive protein <1 mg/dL, those with ≥1mg/dL showed higher body mass index (29.4 ± 6.1 vs. 24.4 ± 4.5 kg/m2; p = 0.009), percent of standard body weight (124.5 ± 25.4 vs. 106.8 ± 17.9 %; p = 0.012), and percent of body fat as assessed by both anthropometry (31.3 ± 9.9 vs. 23.9 ± 9.1%; p = 0.056) and bioimpedance (38.9 ± 6.3 vs. 26.2 ± 12.6 %; p < 0.001). Patients with C-reactive protein ≥1mg/dL also exhibited higher levels of ferritin (701 ± 568 vs. 532 ± 356 ng/mL; p =0.054) and lower total lymphocyte count (median 1838 vs. 1638 mm3; p = 0.001). In conclusion, higher body mass index and body fat markers were associated with C-reactive protein ≥ 1mg/dL, and higher C-reactive protein was associated with immunocompetence impairment evidenced by the lower total lymphocyte count. Our findings confirm the relationship between inflammation, body fat, and immunocompetence, which may be superimposed potentializing the inflammatory status.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.